Apr. 19, 2021 – ACON, one of the professional in-vitro diagnostic products manufacturers, announced today that its Flowflex SARS-CoV-2 Antigen Rapid Test has passed the validation by UK DHSC for mass testing. It showed the remarkable performance of Flowflex SARS-CoV-2 Antigen Rapid Test in the independent validation, as well as in the Comparative Evaluation by German PEI (Paul-Ehrlich-Institut).
 

Flowflex SARS-CoV-2 Antigen Rapid Test has been approved to be one of the best SARS-CoV-2 Antigen Rapid Tests in the industry with high sensitivity and specificity.
 

Founded in 1995, ACON is one of the professional manufacturers in the in-vitro diagnostic (IVD) industry, its product lines include Rapid Test, Molecular Diagnostics, Immunoassay, Diabetes Care and Clinical Chemistry, and the products are available in more than 150 countries.
 

To help control the Covid-19 pandemic globally, ACON has developed a full range of the SARS-CoV-2 testing products. Focusing on the Antigen Rapid Test, ACON has expanded its production capacity to millions of SARS-CoV-2 Antigen rapid tests per day with the state-of-the-art facilities, and the capacity is still keeping expanding dramatically. At ACON, we continuously strive to develop and provide high quality tests to fight against COVID-19 as the world leader in Rapid Test industry.